Reason for request
Inclusion
No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin
No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin
- JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.
Clinical Benefit
| Moderate |
Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate
Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate |
| Insufficient |
- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance
- with insulin : Insufficient for reimbursement by National Health Insurance |
Clinical Added Value
| no clinical added value |
In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.
In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable. |
| Not applicable |
|
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
hf0svsE95yJaE6xb
